67.12 USD
↗ 0.11 (0.16%)AT CLOSE (11:59 AM EDT)
Travere Therapeutics, Inc. Common Stock
TVTXNASDAQ • USD
67.12
↗ 0.00 (0.00%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
67.12
↗ 0.00 (0.00%)
Market: CLOSED
Travere Therapeutics, Inc. Common Stock (TVTX) trades at $67.12 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, TVTX trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Aug 26, 2026.
Open?$66.91
High?$67.50
Low?$65.22
Prev. Close?$67.01
Volume?1.2M
Avg. Volume?1.6M
VWAP?$66.60
Rel. Volume?0.78x
Bid / Ask
Bid?$67.12 × 700
Ask?$68.40 × 100
Spread?$1.28
Midpoint?$67.76
Valuation & Ratios
Market Cap?6.3B
Shares Out?94.3M
Float?88.9M
Float %?95.6%
P/E Ratio?N/A
P/B Ratio?258.01
EPS?-$0.46
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Themes
Address
3611 VALLEY CENTRE DR
SAN DIEGO, CA 92130
Phone: 888-969-7879
SAN DIEGO, CA 92130
Phone: 888-969-7879
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?83
Momentum?57
Short Sent.?40
Piotroski F-Score?3/9Weak
Altman Z-Score?3.46Safe
Confidence?63%Moderate
Short InterestHigh
Short % of Float?13.43%High
Short Interest?11.9M
Days to Cover?5.7
Free Float88.9M
Avg Daily Volume2.1M
Settlement Date2026-08-14
Financial Health
Current Ratio?4.05Strong
Quick Ratio?3.99Strong
Cash Ratio?0.77Adequate
Debt/Equity?24.58High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score33/100
P/E?N/A▾
P/B?258.01HIGH▾
Peers100
S&P3
P/S?10.70HIGH▾
Peers100
S&P7
P/FCF?68.4PRICEY▾
Peers100
S&P5
EV/EBITDA?297.3HIGH▾
Peers100
S&P3
EV/Sales?11.52HIGH▾
Peers100
S&P8
Returns & Efficiency
ROE?-177.2%WEAK▾
S&P3
ROA?-5.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$92.5M
Enterprise Value?$6.8B
Fundamentals ratios updated end of day